Mattia D’Agostino, MD, University of Turin, Turin, Italy, briefly discusses advances that have been made in the tools used to define risk in multiple myeloma, drawing focus on measurable residual disease (MRD), and how these novel prognostic tools may benefit patients in the future. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.